α-actinin-2 CRISPR/Cas9 KO Plasmid (h): sc-401186
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- α-actinin-2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the α-actinin-2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: α-actinin Antibody (H-2): sc-17829
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
α-actinin-2 CRISPR/Cas9 KO Plasmid (h) | sc-401186 | 20 µg | $397.00 |
Overview
ACTN2 encodes α-actinin-2, a Ca2+-modulated actin-binding protein that crosslinks filamentous actin and anchors cytoskeletal networks to adhesion and contractile structures. In striated muscle, α-actinin-2 is a core Z-disc component that organizes sarcomere architecture and supports force transmission through interactions with actin, titin-associated complexes, and other scaffolding proteins. Beyond structural roles, ACTN2 contributes to mechanotransduction and cytoskeletal remodeling pathways that influence cellular tension, signaling at the costamere, and myofibril assembly. Genetic disruption or variation in ACTN2 has been associated with cardiomyopathy phenotypes and altered muscle function, making it relevant for studies of sarcomere integrity and stress-responsive signaling.
α-actinin-2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ACTN2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ACTN2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ACTN2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish α-actinin-2 protein expression.
This CRISPR knockout system enables efficient generation of ACTN2-deficient cell models for investigation of α-actinin-2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ACTN2 exon(s) critical for α-actinin-2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ACTN2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by α-actinin-2 CRISPR/Cas9 KO Plasmid (h) and α-actinin-2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ACTN2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by α-actinin-2 HDR Plasmid (h) and α-actinin-2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ACTN2 homology arms to support homology-directed repair at defined ACTN2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.